Jemperli
FDA Expands Endometrial Cancer Indication for Jemperli With Chemotherapy
The FDA has approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent ...
AUGUST 1, 2024
FDA Approves Jemperli With Chemotherapy for Endometrial Cancer
The FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by ...
AUGUST 2, 2023
Combined Dostarlimab, Standard of Care Improves Survival for Endometrial Cancer Patients
Adding the programmed cell death protein-1 (PD-1) checkpoint inhibitor dostarlimab (Jemperli, GSK) to carboplatin ...
MAY 3, 2023
Jemperli Gets Full Approval for Endometrial Cancer
The FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adult patients with mismatch repair-deficient ...
FEBRUARY 13, 2023
Jemperli Approval Expanded to Treatment of dMMR Solid Tumors
The FDA granted accelerated approval to the programmed cell death receptor-1 agent dostarlimab-gxly (Jemperli, ...
AUGUST 19, 2021
New PD-1 Jemperli Approved to Treat Mismatch Repair–Deficient Endometrial Cancer
The FDA granted accelerated approval to the programmed death receptor-1-blocking antibody dostarlimab-gxly ...
MAY 4, 2021
